Granted Patent B2

US 12,497,604 · App. 19/025,781 · Granted Dec 16, 2025

Inventors: Jeffrey A. Ledbetter (Shoreline, WA); Martha S. Hayden-Ledbetter (Shoreline, WA)

Assignee: Theripion, Inc.

C12N9/22A61P11/00C07K16/241C12N9/16C12Y301/08001A61K38/00C07K2317/31C07K2317/622C07K2319/01C07K2319/30C12Y301/21001

Abstract

Claims (31)

1 . A fusion polypeptide comprising, from an amino terminal position to a carboxyl terminal position, T-L1-X-L2-P, wherein:

T is a biologically active RNase, wherein the RNase has at least 95% identity with the amino acid sequence shown in residues 29-156 of SEQ ID NO:22;

L1 is a first polypeptide linker, wherein L1 is optionally present;

X is an immunoglobulin heavy chain constant region, wherein the immunoglobulin heavy chain constant region is capable of forming dimers and specifically binding the neonatal Fc receptor (FcRn), wherein the immunoglobulin heavy chain constant region is a human immunoglobulin Fc region;

L2 is a second polypeptide linker comprising at least eight amino acid residues; and

P is a biologically active paraoxonase, wherein the paraoxonase has at least 95% identity with the amino acid sequence shown in residues 16-355 or 26-355 of SEQ ID NO:6, and wherein the paraoxonase does not contain an amino terminal leader sequence corresponding to residues 1-15 of SEQ ID NO:6;

wherein the fusion polypeptide comprises an amino acid sequence having at least 95% identity with the amino acid sequence shown in residues 21-740 of SEQ ID NO:48.

2 . The fusion polypeptide of claim 1 , wherein the human Fc region is an Fc variant comprising one or more amino acid substitutions relative to the wild-type human sequence.

3 . The fusion polypeptide of claim 2 , wherein the Fc region is a human γ1 Fc region.

4 . The fusion polypeptide of claim 2 , wherein the Fc region is a human γ1 Fc variant in which

Eu residue C220 is replaced by serine,

Eu residue P238 is replaced by serine, and/or

Eu residue P331 is replaced by serine.

5 . The fusion polypeptide of claim 1 , wherein the Fc region has the amino acid sequence shown in

(i) residues 1-232 or 1-231 of SEQ ID NO:28, or

(ii) residues 159-390 or 159-389 of SEQ ID NO:42.

6 . The fusion polypeptide of claim 1 , wherein the RNase has the amino acid sequence shown in residues 29-156 of SEQ ID NO:22.

7 . The fusion polypeptide of claim 1 , wherein the paraoxonase has the amino acid sequence shown in residues 16-355 of SEQ ID NO:6.

8 . The fusion polypeptide of claim 1 , wherein the fusion polypeptide comprises the amino acid sequence shown in residues 21-740 of SEQ ID NO:48.

9 . A dimeric protein comprising a first fusion polypeptide and a second fusion polypeptide, wherein each of the first and second fusion polypeptides is a fusion polypeptide as defined in claim 1 .

10 . A polynucleotide encoding the fusion polypeptide of claim 1 .

11 . An expression cassette comprising a DNA segment encoding the fusion polypeptide of claim 1 , wherein the DNA segment is operably linked to a promoter.

12 . A vector comprising the expression cassette of claim 11 .

13 . A cultured cell into which has been introduced the expression cassette of claim 11 , wherein the cell expresses the DNA segment.

14 . A method of making a fusion polypeptide, the method comprising:

culturing a cell into which has been introduced the expression cassette of claim 11 , wherein the cell expresses the DNA segment and the encoded fusion polypeptide is produced; and

recovering the fusion polypeptide.

15 . The method of claim 14 , wherein the encoded fusion polypeptide is produced and recovered as a dimeric protein.

16 . A composition comprising:

a dimeric protein of claim 9 ; and

a pharmaceutically acceptable carrier.

Continuity (5)

References Cited (147)